Thiabendazole
Thiabendazole is a benzimidazole anthelmintic that inhibits the helminth-specific enzyme fumarate reductase and interferes with microtubule assembly by binding to beta-tubulin, disrupting energy metabolism and cellular structure in parasitic nematodes. It is used for treatment of strongyloidiasis, cutaneous larva migrans, and visceral larva migrans, and is also used as an antifungal agent in agriculture. Its broad antiparasitic spectrum and mechanism of action on parasite-specific metabolic pathways provide selectivity over mammalian cells.
Molekularmasse
201,2500 g/mol
LogP
2,50
TPSA
69,80 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
2D-Struktur
Cite this structure
Embed this structure
SMILES
c1ccc2[nH]c(-c3cscn3)nc2c1
InChI
InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)
Molecular Formula
C10H7N3S
HBD / HBA
1 / 3
Rotierbare Bindungen
1
Schwere Atome
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Thiabendazole is a benzimidazole anthelmintic that inhibits the helminth-specific enzyme fumarate reductase and interferes with microtubule assembly by binding to beta-tubulin, disrupting energy metabolism and cellular structure in parasitic nematodes. It is used for treatment of strongyloidiasis, cutaneous larva migrans, and visceral larva migrans, and is also used as an antifungal agent in agriculture. Its broad antiparasitic spectrum and mechanism of action on parasite-specific metabolic pathways provide selectivity over mammalian cells.
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Yes, Thiabendazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL625. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5430. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="thiabendazole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/thiabendazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/thiabendazole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/thiabendazole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="thiabendazole"></drugfyi-drug>